DRG Market Assessment reports

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia patient populations, covering 171 countries…

Clarivate Epidemiology’s coverage of AML comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Methicillin-Resistant Staphylococcus Aureus Infections

Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…